# US 2014/0154266 A1 · Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154266 A1
- Document ID: US20140154266A1
- Status: Published application
- Kind: A1
- Application number: 13/902,354
- Filed: 2013-05-24
- Published: 2014-06-05
- Earliest claimed: 2012-05-25
- Assignees: Berg Pharma LLC
- Inventors: Niven Rajin Narain; Rangaprasad Sarangarajan; Vivek K. Vishnudas; Enxuan Jing
- Web page: https://patentgrep.com/patent/US20140154266A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 16/18: against material from animals or humans
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90β inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90β, expression and activity level.

## Claims

### Claim 1

A method of treating a metabolic syndrome in a subject, comprising administering to the subject an HSP90 modulator, thereby treating the metabolic syndrome in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HSP90 modulator is an HSP90 inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the HSP90 inhibitor is an inhibitor of HSP90β.

### Claim 4 (depends on 2)

The method of claim 2, wherein the HSP90 inhibitor is a specific inhibitor of HSP90β.

### Claim 5 (depends on 2, 3)

The method of claim 2 or 3, wherein the HSP90 inhibitor is an inhibitor of HSP90α.

### Claim 6 (depends on 1)

The method of claim 1, wherein the metabolic syndrome comprises type 2 diabetes.

### Claim 7 (depends on 1)

The method of claim 1, wherein the metabolic syndrome comprises type 1 diabetes.

### Claim 8 (depends on 1)

The method of claim 1, wherein the metabolic syndrome comprises insulin resistance.

### Claim 9 (depends on 1)

The method of claim 1, wherein the metabolic syndrome comprises insulin insufficiency.

### Claim 10 (depends on 1)

The method of claim 1, wherein the metabolic syndrome comprises obesity.

### Claim 11 (depends on 1)

The method of claim 1, wherein the metabolic syndrome comprises hyperinsulinemia.

### Claim 12 (depends on 1)

The method of claim 1, wherein the metabolic syndrome comprises impaired glucose tolerance (IGT).

### Claim 13 (depends on 1)

The method of claim 1, wherein a subject with metabolic syndrome exhibits three or more of the following signs:
a) Blood pressure equal to or higher than 130/85 mmHg;
b) Fasting blood glucose equal to or higher than 100 mg/dL;
c) Large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women;
d) Low HDL cholesterol wherein low LDH cholesterol is under 40 mg/dL for men and under 50 mg/dL; and
e) Triglycerides equal to or higher than 150 mg/dL.

### Claim 14 (depends on 2)

The method of claim 2, wherein the HSP90 inhibitor comprises a nucleic acid inhibitor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the nucleic acid inhibitor comprises an antisense nucleic acid molecule.

### Claim 16 (depends on 14)

The method of claim 14, wherein the nucleic acid inhibitor comprises a double stranded nucleic acid molecule.

### Claim 17 (depends on 16)

The method of claim 16, wherein the nucleic acid inhibitor comprises a double stranded RNA selected from the group consisting of an siRNA, a shRNA, and a dicer substrate siRNA (DsiRNA).

### Claim 18 (depends on 2)

The method of claim 2, wherein the HSP90 inhibitor comprises an antibody.

### Claim 19 (depends on 2)

The method of claim 2, wherein the HSP90 inhibitor comprises a small molecule.

### Claim 20 (depends on 19)

The method of claim 19, wherein the small molecule is selected from the group consisting of lonidamine or an analog thereof, celastrol or analog thereof, gedunin or an analog thereof, and coumermycin or an analog thereof.

### Claim 21 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises normalizing a blood glucose level in a subject.

### Claim 22 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises normalizing an Hb1Ac level in a subject.

### Claim 23 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises prevention of at least one complication of diabetes associated with poor circulation.

### Claim 24 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of type 2 diabetes.

### Claim 25 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of type 1 diabetes.

### Claim 26 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of insulin resistance.

### Claim 27 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of insulin insufficiency.

### Claim 28 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of hyperinsulinemia.

### Claim 29 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of impaired glucose tolerance (IGT).

### Claim 30 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of obesity.

### Claim 31 (depends on 1)

The method of claim 1, wherein treating the metabolic syndrome comprises amelioration of at least one of
a) Blood pressure equal to or higher than 130/85 mmHg;
b) Fasting blood glucose equal to or higher than 100 mg/dL;
c) Large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women;
d) Low HDL cholesterol wherein low LDH cholesterol is under 40 mg/dL for men and under 50 mg/dL; and
e) Triglycerides equal to or higher than 150 mg/dL.

### Claim 32 (depends on 31)

The method of claim 31, wherein treating the metabolic syndrome comprises amelioration of elevated blood pressure equal to or higher than 130/85 mmHg.

### Claim 33 (depends on 31)

The method of claim 31, wherein treating the metabolic syndrome comprises amelioration of elevated fasting blood glucose equal to or higher than 100 mg/dL.

### Claim 34 (depends on 31)

The method of claim 31, wherein treating the metabolic syndrome comprises amelioration of large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women.

### Claim 35 (depends on 31)

The method of claim 31, wherein treating the metabolic syndrome comprises amelioration of low HDL cholesterol by increasing HDL cholesterol wherein low LDH cholesterol is under 40 mg/dL for men and under 50 mg/dL.

### Claim 36 (depends on 31)

The method of claim 31, wherein treating the metabolic syndrome comprises amelioration of elevated triglycerides equal to or higher than 150 mg/dL.

### Claim 37 (depends on 1)

The method of claim 1, wherein treating metabolic syndrome comprises amelioration of fatty liver.

### Claim 38 (depends on 1)

The method of claim 1, wherein treating metabolic syndrome comprises modulation of fat deposition.

### Claim 39

A method of diagnosing a metabolic syndrome in a subject comprising:
a) determining a level of HSP90β expression or activity in a sample from the subject; and
b) comparing the level of HSP90β expression or activity in the sample from the subject to a control sample, wherein increased expression or activity of HSP90β in the subject sample as compared to the control sample is indicative of a metabolic disorder in the subject.

### Claim 40

A method of monitoring a metabolic syndrome in a subject comprising:
a) obtaining a sample from the subject at a first time point and at a second time point;
b) determining a level of HSP90β expression or activity at the first time point and the second time point; and
c) comparing the level of HSP90β expression or activity at the first time point to the level of HSP90β expression or activity at the second time point, wherein a change in the level of HSP90β expression or activity at the second time point relative to the first time point is indicative of a change in the metabolic syndrome in the subject.

### Claim 41 (depends on 39, 40)

The method of claim 39 or 40, wherein the level of HSP90β expression comprises the level of expression of the HSP90β protein or the HSP90AB1 gene.

### Claim 42 (depends on 40)

The method of claim 40, wherein an increase in HSP90β expression or activity is indicative of worsening of the metabolic syndrome.

### Claim 43 (depends on 40)

The method of claim 40, wherein a decrease in HSP90β expression or activity is indicative of an improvement in the metabolic syndrome.

### Claim 44 (depends on 39, 40)

The method of claim 39 or 40, wherein the metabolic syndrome comprises type 2 diabetes.

### Claim 45 (depends on 39, 40)

The method of claim 39 or 40, wherein the metabolic syndrome comprises type 1 diabetes.

### Claim 46 (depends on 39, 40)

The method of claim 39 or 40, wherein the metabolic syndrome comprises type insulin resistance.

### Claim 47 (depends on 39, 40)

The method of claim 39 or 40, wherein the metabolic syndrome comprises insulin insufficiency.

### Claim 48 (depends on 39, 40)

The method of claim 39 or 40, wherein the metabolic syndrome comprises obesity.

### Claim 49 (depends on 39, 40)

The method of claim 39 or 40, wherein the metabolic syndrome comprises hyperinsulinemia.

### Claim 50 (depends on 39, 40)

The method of claim 39 or 40, wherein the metabolic syndrome comprises impaired glucose tolerance (IGT).

### Claim 51 (depends on 39, 40)

The method of claim 39 or 40, wherein the subject with metabolic syndrome further exhibits one or more of the following signs:
a) Blood pressure equal to or higher than 130/85 mmHg;
b) Fasting blood glucose equal to or higher than 100 mg/dL;
c) Large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women;
d) Low HDL cholesterol wherein low LDH cholesterol is under 40 mg/dL for men and under 50 mg/dL; and
e) Triglycerides equal to or higher than 150 mg/dL.
